Taurochenodeoxycholic Acid

"Taurochenodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.

Descriptor ID

D013655

MeSH Number(s)

D02.455.326.146.100.850.875.900.875

D02.886.645.600.055.850.800.900.875

D04.808.105.225.272.150.850

D04.808.105.225.272.925.875

D04.808.105.225.900.900.870

D04.808.221.430.342.300.900

D04.808.221.430.342.900.910

D04.808.221.430.873.920.900

Concept/Terms

Taurochenodeoxycholic Acid

Taurine Chenodeoxycholate

Below are MeSH descriptors whose meaning is more general than "Taurochenodeoxycholic Acid".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Acyclic [D02.455.326]
Alkanes [D02.455.326.146]
Alkanesulfonic Acids [D02.455.326.146.100]
Taurine [D02.455.326.146.100.850]
Taurocholic Acid [D02.455.326.146.100.850.875]
Taurodeoxycholic Acid [D02.455.326.146.100.850.875.900]
Taurochenodeoxycholic Acid [D02.455.326.146.100.850.875.900.875]
Sulfur Compounds [D02.886]
Sulfur Acids [D02.886.645]
Sulfonic Acids [D02.886.645.600]
Alkanesulfonic Acids [D02.886.645.600.055]
Taurine [D02.886.645.600.055.850]
Taurocholic Acid [D02.886.645.600.055.850.800]
Taurodeoxycholic Acid [D02.886.645.600.055.850.800.900]
Taurochenodeoxycholic Acid [D02.886.645.600.055.850.800.900.875]
Polycyclic Compounds [D04]
Steroids [D04.808]
Bile Acids and Salts [D04.808.105]
Cholic Acids [D04.808.105.225]
Deoxycholic Acid [D04.808.105.225.272]
Chenodeoxycholic Acid [D04.808.105.225.272.150]
Taurochenodeoxycholic Acid [D04.808.105.225.272.150.850]
Taurodeoxycholic Acid [D04.808.105.225.272.925]
Taurochenodeoxycholic Acid [D04.808.105.225.272.925.875]
Taurocholic Acid [D04.808.105.225.900]
Taurodeoxycholic Acid [D04.808.105.225.900.900]
Taurochenodeoxycholic Acid [D04.808.105.225.900.900.870]
Cholanes [D04.808.221]
Cholic Acids [D04.808.221.430]
Deoxycholic Acid [D04.808.221.430.342]
Chenodeoxycholic Acid [D04.808.221.430.342.300]
Taurochenodeoxycholic Acid [D04.808.221.430.342.300.900]
Taurodeoxycholic Acid [D04.808.221.430.342.900]
Taurochenodeoxycholic Acid [D04.808.221.430.342.900.910]
Taurocholic Acid [D04.808.221.430.873]
Taurodeoxycholic Acid [D04.808.221.430.873.920]
Taurochenodeoxycholic Acid [D04.808.221.430.873.920.900]

Below are MeSH descriptors whose meaning is related to "Taurochenodeoxycholic Acid".

Below are MeSH descriptors whose meaning is more specific than "Taurochenodeoxycholic Acid".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Taurochenodeoxycholic Acid" by people in Harvard Catalyst Profiles by year, and whether "Taurochenodeoxycholic Acid" was a major or minor topic of these publication.

Bar chart showing 15 publications over 11 distinct years, with a maximum of 3 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1998	0	1	1
2006	1	0	1
2007	0	1	1
2009	0	1	1
2011	2	1	3
2013	0	1	1
2016	1	0	1
2019	0	2	2
2020	2	0	2
2022	0	1	1

Below are the most recent publications written about "Taurochenodeoxycholic Acid" by people in Profiles.

Changes in circulating bile acid subtypes in response to weight-loss diets are associated with improvements in glycemic status and insulin resistance: The POUNDS Lost trial. Metabolism. 2022 11; 136:155312.

View in: PubMed
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021 01; 63(1):31-39.

View in: PubMed
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. 2020 09 03; 383(10):919-930.

View in: PubMed
GRP78 translocation to the cell surface and O-GlcNAcylation of VE-Cadherin contribute to ER stress-mediated endothelial permeability. Sci Rep. 2019 07 25; 9(1):10783.

View in: PubMed
c-Myc Inhibitor 10074-G5 Induces Murine and Human Hematopoietic Stem and Progenitor Cell Expansion and HDR Modulator Rad51 Expression. Curr Cancer Drug Targets. 2019; 19(6):479-494.

View in: PubMed
A Stem Cell-Based Screening Platform Identifies Compounds that Desensitize Motor Neurons to Endoplasmic Reticulum Stress. Mol Ther. 2019 01 02; 27(1):87-101.

View in: PubMed
Bile acid TUDCA improves insulin clearance by increasing the expression of insulin-degrading enzyme in the liver of obese mice. Sci Rep. 2017 11 01; 7(1):14876.

View in: PubMed
A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016 Nov; 95(47):e5391.

View in: PubMed
Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury? Neurocrit Care. 2016 08; 25(1):153-66.

View in: PubMed
The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism. 2016 Mar; 65(3):54-63.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Sci Rep
Metabolism
Neurocrit Care
N Engl J Med
Muscle Nerve
Medicine (Baltimore)
FEBS Lett
Dig Dis Sci
Diabetes
Cell Death Dis